Original Article
The Cost of Self-Reported Penicillin Allergy: A Systematic Review

https://doi.org/10.1016/j.jaip.2017.12.033Get rights and content
Under a Creative Commons license
open access

Background

Patients who report a penicillin (PCN) allergy receive suboptimal antibiotic therapy compared with patients not reporting an allergy. However, a majority of patients who report PCN allergy are not truly allergic on confirmatory testing. Ruling out PCN allergy by testing may improve clinical and economic outcomes for patients with reported allergies requiring antibiotic therapy.

Objective

The objective of this study was to summarize clinical and economic outcomes associated with PCN allergy and provide recommendations for future cost-effectiveness analyses for PCN allergy testing.

Methods

A literature search was conducted using SCOPUS, EMBASE, and PubMed, including all articles published any date through April 25, 2017 (PROSPERO Registration number 42017064112). A total of 1518 abstracts were found during the initial search with 96 duplicates, for a total of 1422 articles for screening. Thirty articles were included for qualitative synthesis and full data extraction.

Results

The majority of the studies included had an observational design focusing on inpatient admissions. The most frequently measured outcome in the context of PCN allergy was optimizing antibiotic therapy. Patients with PCN allergy were found to have direct drug costs during inpatient admission ranging from no difference to an additional $609/patient compared with patients without PCN allergy. Outpatient prescription costs were estimated from $14 to $193/patient higher for PCN allergic patients. Total inpatient costs were less for patients without PCN allergy with average savings from $1145 to $4254/patient.

Conclusions

Evaluations of clinical and economic outcomes of PCN allergy are primarily observational and focus on inpatient populations. Long-term relationships between PCN allergy and clinical and economic outcomes are unknown.

Key words

Penicillin allergy
β-Lactam
Outcomes
Cost

Abbreviations used

PCN
Penicillin
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Cited by (0)

This study was supported by an unrestricted educational grant by ALK. The funding source had no role in the design and conduct of the study; collection, management, and analysis of the data; or preparation, review, and approval of the manuscript.

Conflicts of interest: The authors' institution received a grant from ALK for this study. T. J. Mattingly reports personal fees from Summit Therapeutics and Paratek Pharmaceuticals outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.